Friday, July 6, 2018

Biomarkers for ALK and ROS1 in Lung Cancer: Immunohistochemistry and Fluorescent In Situ Hybridization

Peter P. LukMBBSChristina I. SelingerPhDAnnabelle MaharMBBSWendy A. CooperMBBS, PhD
From the Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, Australia (Drs Luk, Selinger, Mahar, and Cooper); Central Clinical School, University of Sydney, Sydney, Australia (Dr Cooper); and the School of Medicine, Western Sydney University, Sydney, Australia (Dr Cooper).
The authors have no relevant financial interest in the products or companies described in this article.
The manuscript is based on an invited talk presented at the Pulmonary Pathology Society Biennial Meeting; June 14, 2017; Chicago, Illinois.
Corresponding author: Wendy A. Cooper, MBBS, PhD, Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Missenden Rd, Camperdown NSW 2050, Australia (email: ).
Context.— A small proportion of non–small cell lung cancers harbor rearrangements of ALK or ROS1 genes, and these tumors are sensitive to targeted tyrosine kinase inhibitors. It is crucial for pathologists to accurately identify tumors with these genetic alterations to enable patients to access optimal treatments and avoid unnecessary side effects of less effective agents. Although a number of different techniques can be used to identify ALK- and ROS1-rearranged lung cancers, immunohistochemistry and fluorescence in situ hybridization are the mainstays.
Objective.— To review the role of immunohistochemistry in assessment of ALK and ROS1 rearrangements in lung cancer, focusing on practical issues in comparison with other modalities such as fluorescence in situ hybridization.
Data Sources.— This manuscript reviews the current literature on ALK and ROS1 detection using immunohistochemistry and fluorescence in situ hybridization as well as current recommendations.
Conclusions.— Although fluorescence in situ hybridization remains the gold standard for detecting ALK and ROS1rearrangement in non–small cell lung cancer, immunohistochemistry plays an important role and can be an effective screening method for detection of these genetic alterations, or a diagnostic test in the setting of ALK.

1 comment:

  1. Good day to all am Valeria Miguel Ángel From USA..Texas am so happy sharing this great testimony on here, I was diagnose of Stage IV colon cancer.i was checking for solution in the internet then miraculously i came Across Dr Itua the powerful herbalist that Cure Numerous Diseases such as-Thyroid Cancer,Uterine cancer,Fibroid,Angiopathy, Ataxia,Arthritis,Amyotrophic Lateral Scoliosis,Brain Tumor,Fibromyalgia,Fluoroquinolone ToxicityBladder cancer,Brain cancer,Hiv,Herpes,Esophageal cancer,Gallbladder cancer,Gestational trophoblastic disease,Head and neck cancer,Hodgkin lymphoma
    Intestinal cancer,Kidney cancer,Hpv,Lung cancer,Melanoma,Mesothelioma,Multiple myeloma,Neuroendocrine tumors
    Non-Hodgkin lymphoma,Oral cancer,Ovarian cancer,Sinus cancer,Hepatitis A,B/C,Skin cancer,Soft tissue sarcoma,Pancreative Cancer,Spinal cancer,Stomach cancer,Vaginal cancer,Vulvar cancer,
    Testicular cancer,Tach Diseases,Leukemia,Liver cancer,Throat cancer,
    Syndrome Fibrodysplasia Ossificans ProgresSclerosis,Alzheimer's disease,Chronic Diarrhea,Copd,Parkinson,Als,Adrenocortical carcinoma  Infectious mononucleosis. ,so I contacted him base on the testimonies I?m seeing about him on the internet, I was cured too by him, kindly contact him today through his email he can help you..drituaherbalcenter@gmail.com and his herbal medicines will set you free from any human diseases,all thank to you Dr Itua for your kindly help in my life his Mobile number Whatsapp.+2348149277967

    ReplyDelete